arrow
A

Alexander Parkhomenko

Harvard Medical School
H指数:77
被引数:8.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial
2024-08-190
OA
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial

依格列净对急性心肌梗死后心力衰竭预后的影响: 来自empact-mi试验的见解

2024-05-2114
OAAI
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction
2024-05-0226
PRE
Empagliflozin after Acute Myocardial Infarction

急性心肌梗死后的依格列净

2024-04-2567
PRE
Global Variations in Heart Failure Etiology, Management, and Outcomes
2023-05-1644
OA
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial
2023-05-017
OA
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial

纤溶和抗血小板治疗ST段抬高型心肌梗死患者的吗啡和临床结局: 来自TREAT试验的见解

2022-09-013
PRE
Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI

ACC/AHA与ESC/EAS ldl-c建议对降低ASCVD残余风险的影响: 达芬奇的模拟研究

2022-05-146
OAAI
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

慢性冠状动脉或外周动脉疾病患者长期使用利伐沙班和阿司匹林联合治疗: COMPASS试验开放标签扩展期间的结果

2022-04-0618
OA
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial
2022-01-0176
OA
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials (vol 11, pg 2160, 2020)
2021-12-200
OA
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction
2021-12-1326
OA
The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

静脉注射铁羧基麦芽糖对铁缺乏的急性心力衰竭患者的heatlh相关生活质量的影响: affirm-ahf研究的结果

2021-06-0371
OAAI
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
2021-05-0818
OAAI
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention Insights From the AUGUSTUS Trial
2021-03-239
OA
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
2021-02-1625
OAAI